Cervical Cancer Test Market & Screening Population Analysis, By Screening Type (Pap Smear, HPV DNA, VIA) - Global Forecast To 2022

Published Date: Jul-2017 | Pages:306| Category:Pharmaceutical | Report Id-72932

    Single User Price-$ 1,890.00 | Multi User Price-$ 2,500.00

Cervical cancer is one of the most prevalent forms of cancer affecting women all over the world. In most cases, the disease is attributed to genital Human Papilloma Virus (HPV) infection. As cervical cancer is a disease with long latent period, early detection and treatment of precancerous lesions is known to be highly effective in women who regularly participate in screening programs. The death rate due to cervical cancer has dropped in many developed countries, thus indicating the growing adoption of screening procedures, such as Pap test and HPV testing.

The cervical cancer test market is driven by growth in aging female population and rising prevalence rate of cervical cancer, high incidence rate of HPV infections, rising incidences of teenage sexual cases, increasing number of awareness programs for cervical cancer screening, introduction of low cost VIA test and government initiatives and funding. However, lack of healthcare infrastructure and awareness regarding cervical cancer screening are the major restraints for cervical cancer testing market.

Key Highlights of the Report

• Cervical cancer is amongst one of the most common causes of deaths in the U.S. women. United States alone captured over 40 percent share of the global cervical cancer test market.

• Pap test held a majority share of the cervical cancer screening market on account of the high efficiency of this test, however, HPV test is steadily gaining prominence.

• VIA is the best screening option where access to Pap smear tests and HPV test is not available.

• In 2016, Global cervical cancer test population was estimated at XXX Million.

• Cervical cancer incidence rate in Europe is estimated at 10.6 per 100,000 women population.

• Asia Pacific and North American region are competing closely with each other to grab maximum share of the cervical cancer test population.

• Indonesia, China, India and Japan captures highest share of the Asian cervical cancer test population.

• North America captures highest share of the global cervical cancer test market followed by the European region.

• Germany, United Kingdom and France are the other top three leaders in cervical cancer test market.

• China and India are the top contributor to the VIA test market.

• Australia’s National Cervical Cancer Screening Program will change from December 2017.


iGATE RESEARCH report titled “Cervical Cancer Test Market & Screening Population Analysis, By Screening Type (Pap Smear, HPV DNA, VIA) - Global Forecast to 2022” is a 306 Page report with 238 Figures and 25 Tables. This report provides a comprehensive assessment of the Cervical Cancer Test (Pap Smear, HPV DNA Test and VIA) Screening Market in terms of Value and Volume terms.

The 20 Countries covered in the report have been analyzed from 4 View Points:

1. Cervical Cancer Test Population (2007 - 2022)

• Pap Smear Test Population (2007 - 2022)
• HPV DNA Test population (2007 - 2022)
• VIA Test Population (2007 - 2022)

2. Cervical Cancer Mortality

3. Cervical Cancer Test Market (2007 - 2022)

• Pap Smear Test Market (2007 - 2022)
• HPV DNA Test Market (2007 - 2022)
• VIA Test Market (2007 - 2022)

4. Global Cervical Cancer Test Market - Driving Factors and Challenges


Cervical Cancer Test Market & Screening Population Analysis - 20 Countries Covered

1. United States
2. Canada
3. United Kingdom
4. France
5. Germany
6. Italy
7. Spain
8. Sweden
9. Switzerland
10. Norway
11. Netherlands
12. Japan
13. South Korea
14. Singapore
15. Malaysia
16. Australia
17. India
18. China
19. Thailand
20. Indonesia

Data Sources

iGATE RESEARCH employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by iGATE Research dedicated team of qualified professionals with deep industry experience and expertise.

Research Methodologies

Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interview, etc.

Secondary Research Methodologies: Printable and Non-printable sources, Newspaper, Magazine and Journal Content, Government and NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report, Government Agencies, Libraries and Local Councils and a large number of Paid Databases.

1. Executive Summary

2. Global Cervical Cancer Test (Screening) Population & Forecast (2007 - 2022)

2.1 By Region - Cervical Cancer Test (Screening) Population & Forecast
2.1.1 North America Cervical Cancer Test (Screening) Population & Forecast
2.1.2 Europe Cervical Cancer Test (Screening) Population & Forecast
2.1.3 Asia Pacific Cervical Cancer Test (Screening) Population & Forecast

3. Global Cervical Cancer Test (Screening) Market & Forecast (2007 - 2022)

3.1 By Region - Cervical Cancer Test (Screening) Market & Forecast
3.1.1 North America Cervical Cancer Test (Screening) Market & Forecast
3.1.2 Europe Cervical Cancer Test (Screening) Market & Forecast
3.1.3 Asia Pacific Cervical Cancer Test (Screening) Market & Forecast

4. Global Cervical Cancer Test (Screening) Market & Forecast (2007 - 2022) - By Segment

4.1 Global Cervical Cancer Pap Smear Test (Screening) Market & Forecast
4.2 Global Cervical Cancer HPV DNA Test (Screening) Market & Forecast
4.3 Global Cervical Cancer Visual Inspection with Acetic Acid (VIA) Test (Screening) Market & Forecast

5. Cervical Cancer Test (Screening) Population Share & Forecast (2007 - 2022)

5.1 Global Cervical Cancer Test (Screening) Population Share & Forecast - Regional Analysis
5.2 Global Cervical Cancer Test (Screening) Population Share & Forecast - Country Wise Analysis

6. Global Cervical Cancer Test (Screening) Market Share & Forecast (2007 - 2022)
6.1 Global Cervical Cancer Test (Screening) Market Share & Forecast - Regional Analysis
6.2 Global Cervical Cancer Test (Screening) Market Share & Forecast - Country Wise Analysis
6.3 Global Pap Smear Test (Screening) Market Share & Forecast - Country Wise Analysis
6.4 Global HPV DNA Test (Screening) Market Share & Forecast - Country Wise Analysis
6.5 Global VIA Test (Screening) Market Share & Forecast - Country Wise Analysis
6.6 By Region - Cervical Cancer Test (Screening) Market & Forecast
6.6.1 North America Cervical Cancer Test (Screening) Market Share & Forecast - Country Wise Analysis
6.6.2 Europe Cervical Cancer Test (Screening) Market Share & Forecast - Country Wise Analysis
6.6.3 Asia Pacific Cervical Cancer Test (Screening) Market Share & Forecast - Country Wise Analysis

7. United States - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)
7.1 United States Cervical Cancer Test (Screening) Population and Forecast
7.1.1 United States Cervical Cancer Pap Smear Test Population & Forecast
7.1.2 United States Cervical Cancer HPV DNA Test Population & Forecast
7.2 United States Cervical Cancer Mortality
7.3 United States Cervical Cancer Test (Screening) Market and Forecast
7.3.1 United States Cervical Cancer Pap Smear Test Market & Forecast
7.3.2 United States Cervical Cancer HPV DNA Test Market & Forecast

8. Canada - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)
8.1 Canada Cervical Cancer Test (Screening) Population and Forecast
8.1.1 Canada Cervical Cancer Pap Smear Test Population & Forecast
8.1.2 Canada Cervical Cancer HPV DNA Test Population & Forecast
8.2 Canada Cervical Cancer Mortality
8.3 Canada Cervical Cancer Test (Screening) Market and Forecast
8.3.1 Canada Cervical Cancer Pap Smear Test Market & Forecast
8.3.2 Canada Cervical Cancer HPV DNA Test Market & Forecast

9. United Kingdom - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)
9.1 United Kingdom Cervical Cancer Test (Screening) Population and Forecast
9.1.1 United Kingdom Cervical Cancer Pap Smear Test Population & Forecast
9.1.2 United Kingdom Cervical Cancer HPV DNA Test Population & Forecast
9.2 United Kingdom Cervical Cancer Mortality
9.3 United Kingdom Cervical Cancer Test (Screening) Market and Forecast
9.3.1 United Kingdom Cervical Cancer Pap Smear Test Market & Forecast
9.3.2 United Kingdom Cervical Cancer HPV DNA Test Market & Forecast

10. France - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)
10.1 France Cervical Cancer Test (Screening) Population and Forecast
10.1.1 France Cervical Cancer Pap Smear Test Population & Forecast
10.1.2 France Cervical Cancer HPV DNA Test Population & Forecast
10.2 France Cervical Cancer Test (Screening) Market and Forecast
10.2.1 France Cervical Cancer Pap Smear Test Market & Forecast
10.2.2 France Cervical Cancer HPV DNA Test Market & Forecast

11. Germany - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)
11.1 Germany Cervical Cancer Test (Screening) Population and Forecast
11.1.1 Germany Cervical Cancer Pap Smear Test Population & Forecast
11.1.2 Germany Cervical Cancer HPV DNA Test Population & Forecast
11.2 Germany Cervical Cancer Test (Screening) Market and Forecast
11.2.1 Germany Cervical Cancer Pap Smear Test Market & Forecast
11.2.2 Germany Cervical Cancer HPV DNA Test Market & Forecast

12. Italy - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)
12.1 Italy Cervical Cancer Test (Screening) Population and Forecast
12.1.1 Italy Cervical Cancer Pap Smear Test Population & Forecast
12.1.2 Italy Cervical Cancer HPV DNA Test Population & Forecast
12.2 Italy Cervical Cancer Test (Screening) Market and Forecast
12.2.1 Italy Cervical Cancer Pap Smear Test Market & Forecast
12.2.2 Italy Cervical Cancer HPV DNA Test Market & Forecast

13. Spain - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)

13.1 Spain Cervical Cancer Test (Screening) Population and Forecast
13.1.1 Spain Cervical Cancer Pap Smear Test Population & Forecast
13.1.2 Spain Cervical Cancer HPV DNA Test Population & Forecast
13.2 Spain Cervical Cancer Test (Screening) Market and Forecast
13.2.1 Spain Cervical Cancer Pap Smear Test Market & Forecast
13.2.2 Spain Cervical Cancer HPV DNA Test Market & Forecast

14. Sweden - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)
14.1 Sweden Cervical Cancer Test (Screening) Population and Forecast
14.1.1 Sweden Cervical Cancer Pap Smear Test Population & Forecast
14.1.2 Sweden Cervical Cancer HPV DNA Test Population & Forecast
14.2 Sweden Cervical Cancer Test (Screening) Market and Forecast
14.2.1 Sweden Cervical Cancer Pap Smear Test Market & Forecast
14.2.2 Sweden Cervical Cancer HPV DNA Test Market & Forecast

15. Switzerland - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)
15.1 Switzerland Cervical Cancer Test (Screening) Population and Forecast
15.1.1 Switzerland Cervical Cancer Pap Smear Test Population & Forecast
15.1.2 Switzerland Cervical Cancer HPV DNA Test Population & Forecast
15.2 Switzerland Cervical Cancer Test (Screening) Market and Forecast
15.2.1 Switzerland Cervical Cancer Pap Smear Test Market & Forecast
15.2.2 Switzerland Cervical Cancer HPV DNA Test Market & Forecast

16. Norway - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)
16.1 Norway Cervical Cancer Test (Screening) Population and Forecast
16.1.1 Norway Cervical Cancer Pap Smear Test Population & Forecast
16.1.2 Norway Cervical Cancer HPV DNA Test Population & Forecast
16.2 Norway Cervical Cancer Test (Screening) Market and Forecast
16.2.1 Norway Cervical Cancer Pap Smear Test Market & Forecast
16.2.2 Norway Cervical Cancer HPV DNA Test Market & Forecast

17. Netherlands - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)
17.1 Netherlands Cervical Cancer Test (Screening) Population and Forecast
17.1.1 Netherlands Cervical Cancer Pap Smear Test Population & Forecast
17.1.2 Netherlands Cervical Cancer HPV DNA Test Population & Forecast
17.2 Netherlands Cervical Cancer Test (Screening) Market and Forecast
17.2.1 Netherlands Cervical Cancer Pap Smear Test Market & Forecast
17.2.2 Netherlands Cervical Cancer HPV DNA Test Market & Forecast

18. Japan - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)
18.1 Japan Cervical Cancer Test (Screening) Population and Forecast
18.1.1 Japan Cervical Cancer Pap Smear Test Population & Forecast
18.1.2 Japan Cervical Cancer HPV DNA Test Population & Forecast
18.2 Japan Cervical Cancer Test (Screening) Market and Forecast
18.2.1 Japan Cervical Cancer Pap Smear Test Market & Forecast
18.2.2 Japan Cervical Cancer HPV DNA Test Market & Forecast

19. South Korea - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)
19.1 South Korea Cervical Cancer Test (Screening) Population and Forecast
19.1.1 South Korea Cervical Cancer Pap Smear Test Population & Forecast
19.1.2 South Korea Cervical Cancer HPV DNA Test Population & Forecast
19.2 South Korea Cervical Cancer Mortality
19.3 South Korea Cervical Cancer Test (Screening) Market and Forecast
19.3.1 South Korea Cervical Cancer Pap Smear Test Market & Forecast
19.3.2 South Korea Cervical Cancer HPV DNA Test Market & Forecast

20. Singapore - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)
20.1 Singapore Cervical Cancer Test (Screening) Population and Forecast
20.1.1 Singapore Cervical Cancer Pap Smear Test Population & Forecast
20.1.2 Singapore Cervical Cancer HPV DNA Test Population & Forecast
20.2 Singapore Cervical Cancer Test (Screening) Market and Forecast
20.2.1 Singapore Cervical Cancer Pap Smear Test Market & Forecast
20.2.2 Singapore Cervical Cancer HPV DNA Test Market & Forecast

21. Malaysia - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)
21.1 Malaysia Cervical Cancer Test (Screening) Population and Forecast
21.1.1 Malaysia Cervical Cancer Pap Smear Test Population & Forecast
21.1.2 Malaysia Cervical Cancer HPV DNA Test Population & Forecast
21.2 Malaysia Cervical Cancer Test (Screening) Market and Forecast
21.2.1 Malaysia Cervical Cancer Pap Smear Test Market & Forecast
21.2.2 Malaysia Cervical Cancer HPV DNA Test Market & Forecast

22. India - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)
22.1 India Cervical Cancer Test (Screening) Population and Forecast
22.1.1 India Cervical Cancer Pap Smear Test Population & Forecast
22.1.2 India Cervical Cancer HPV DNA Test Population & Forecast
22.1.3 India Cervical Cancer VIA Test Population & Forecast
22.2 India Cervical Cancer Test (Screening) Market and Forecast
22.2.1 India Cervical Cancer Pap Smear Test Market & Forecast
22.2.2 India Cervical Cancer HPV DNA Test Market & Forecast
22.2.3 India Cervical Cancer VIA Test Market & Forecast

23. China - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)
23.1 China Cervical Cancer Test (Screening) Population and Forecast
23.1.1 China Cervical Cancer Pap Smear Test Population & Forecast
23.1.2 China Cervical Cancer HPV DNA Test Population & Forecast
23.1.3 China Cervical Cancer VIA Test Population & Forecast
23.2 China Cervical Cancer Test (Screening) Market and Forecast
23.2.1 China Cervical Cancer Pap Smear Test Market & Forecast
23.2.2 China Cervical Cancer HPV DNA Test Market & Forecast
23.2.3 China Cervical Cancer VIA Test Market & Forecast

24. Thailand - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)
24.1 Thailand Cervical Cancer Test (Screening) Population and Forecast
24.1.1 Thailand Cervical Cancer Pap Smear Test Population & Forecast
24.1.2 Thailand Cervical Cancer VIA Test Population & Forecast
24.2 Thailand Cervical Cancer Test (Screening) Market and Forecast
24.2.1 Thailand Cervical Cancer Pap Smear Test Market & Forecast
24.2.2 Thailand Cervical Cancer VIA Test Market & Forecast

25. Indonesia - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)
25.1 Indonesia Cervical Cancer Test (Screening) Population and Forecast
25.1.1 Indonesia Cervical Cancer Pap Smear Test Population & Forecast
25.1.2 Indonesia Cervical Cancer HPV DNA Test Population & Forecast
25.1.3 Indonesia Cervical Cancer VIA Test Population & Forecast
25.1.4 Indonesia Cervical Cancer Both (Pap Smear & VIA) Test Population & Forecast
25.2 Indonesia Cervical Cancer Test (Screening) Market and Forecast
25.2.1 Indonesia Cervical Cancer Pap Smear Test Market & Forecast
25.2.2 Indonesia Cervical Cancer HPV DNA Test Market & Forecast
25.2.3 Indonesia Cervical Cancer VIA Test Market & Forecast
25.2.4 Indonesia Cervical Cancer Both (Pap Smear & VIA) Test Market & Forecast

26. Australia - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2017)
26.1 Australia Cervical Cancer Test (Screening) Population and Forecast
26.1.1 Australia Cervical Cancer Pap Smear Test Population & Forecast
26.1.2 Australia Cervical Cancer HPV DNA Test Population & Forecast
26.2 Australia Cervical Cancer Mortality
26.3 Australia Cervical Cancer Test (Screening) Market and Forecast
26.3.1 Australia Cervical Cancer Pap Smear Test Market & Forecast
26.3.2 Australia Cervical Cancer HPV DNA Test Market & Forecast

27. Cervical Cancer Test (Screening) Market - Driving Factors

27.1 Introduction of Low Cost VIA Test
27.1.1 Countries Offering VIA Test via National Programs
27.1.2 Countries Offering VIA Test via Pilot Programs
27.2 High Prevalence of HPV Infected Patients Globally
27.3 Rising Incidence of Teenage Sexual Cases Globally

28. Cervical Cancer Test (Screening) Market - Challenges

28.1 Lack of Appropriate Healthcare Infrastructure
28.2 Introduction of HPV Vaccination Programs Worldwide

Request Sample